

# Analysis of Patient Access to Personalized Oncology Medicines in Türkiye

Okcun S<sup>1</sup>, Ozturk F,<sup>1</sup> Kockaya G<sup>1</sup>

<sup>1</sup> Econix Research, Analysis, and Consulting Inc., Istanbul, Türkiye

## Introduction


- Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work the best for each patient or use medical interventions to alter molecular mechanisms that impact health<sup>1</sup>.
- In this study, it was aimed to examine the access, license and reimbursement status of personalized oncology medicines approved in Türkiye.

## Methods

- In the study the list of personalized oncology medicines was obtained from official websites of FDA and EMA.
- A search was conducted using the drug substance and trade names on the Abroad Medicines List, Annex-4A List of Reimbursed Medicines, Annex-4C Abroad Medicine Price List, Licensed Products List published by the Turkish Medicines and Medical Devices Agency, Social Security Institution and ECONALiX Medicine Databank to determine the access of patients to these medicines in Türkiye.
- The descriptive analyzes for the study were conducted through the Microsoft Office Excel program.

## Results

- As a result of the analysis, it was determined that there are 116 medicines substances in the lists published by the FDA or EMA as personalized oncology medicines.
- Patient access is available for 63 of 116 medicines substances in Türkiye.
- While 43 of the 63 medicines substances have marketing authorization approval (MAA) in Türkiye, 20 of them do not have any MAA but they can be imported as named patient sales (NPS).
- 30 of the 43 medicines with MAA are under reimbursement coverage (Annex-4A).
- Only 6 of the 20 NPS medicines are under reimbursement coverage (Annex-4C).
- As a summary, 36 of 116 personalized oncology medicines have reimbursement in Türkiye either with MAA or NPS.



## Conclusions

- Personalized oncology has been seen as the main cancer treatment in recent years, as it provides the right cancer patient with the right care at the right time, providing positive results on health outcomes and treatment costs.
- Increasing access to personalized oncology medicines in Türkiye for better disease prevention, more accurate diagnoses, safer medicine prescriptions, fewer diseases and more effective treatments is a crucial need for policy makers to address.

## References

1. Personalized Medicine Coalition. Personalized Medicine At FDA, The Scope & Significance of Progress in 2021.

